The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized, double-blind, placebo-controlled, phase II trial of first-line platinum/docetaxel with or without erlotinib (E) in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinomas (HNSCCs).
 
William Nassib William
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Clovis Oncology
Speakers' Bureau - Boehringer Ingelheim
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); OSI Pharmaceuticals (Inst)
 
Lei Feng
No Relationships to Disclose
 
Merrill S. Kies
No Relationships to Disclose
 
Salmaan Ahmed
No Relationships to Disclose
 
George R. Blumenschein
No Relationships to Disclose
 
Bonnie S. Glisson
No Relationships to Disclose
 
Erminia Massarelli
No Relationships to Disclose
 
Faye M. Johnson
No Relationships to Disclose
 
Charles Lu
No Relationships to Disclose
 
Vassiliki Papadimitrakopoulou
Consulting or Advisory Role - ARIAD; AstraZeneca; Biothera; Clovis Oncology; Genentech; Genentech; Gensignia Life Sciences; Janssen; Lilly; Merck
Research Funding - ACEA Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Kathryn A. Gold
Honoraria - Roche/Genentech
Consulting or Advisory Role - ARIAD
Research Funding - ARIAD; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Pharmacyclics; Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca
 
Rachel Leigh Theriault
No Relationships to Disclose
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Calithera Biosciences; Genentech; Medivation; Novartis; Oncomed; Synta
Research Funding - AstraZeneca (Inst)
 
Edward S. Kim
Honoraria - AstraZeneca; Boehringer Ingelheim; Celgene; Lilly
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celgene; Lilly